Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 versus TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN-HBC 7% vs TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HBC 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting anabolism and tissue repair in patients with high metabolic stress.
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Intravenous infusion; typical adult dose: 1.0-1.5 g/kg/day of amino acids, administered as a continuous infusion over 12-24 hours.
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
None Documented
None Documented
Not applicable; amino acids are continuously metabolized and recycled. For individual amino acids, terminal half-life ranges from minutes to hours depending on metabolic demand.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Renal: >90% as amino acids and metabolites; minimal biliary/fecal elimination.
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution